Stay updated on Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial
Sign up to get notified when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.

Latest updates to the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check21 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check50 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check64 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding Temelimab's efficacy for treating neuropsychiatric symptoms in Post-COVID-19 Syndrome, while adding a new EudraCT number and a revision update.SummaryDifference24%
- Check72 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.